Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio, Inc. CFO Hao-Yuan Chuang reported vesting of 5,000 ordinary shares on October 29, 2026, after certain performance criteria were met for RSUs granted on September 15, 2025. His reported direct holdings following the transaction were 180,264 ordinary shares. He also reported 30,000 ordinary shares held indirectly through ESHJ Ltd., a company wholly beneficially owned by him; those shares had been transferred to ESHJ Ltd. on June 8, 2026.
BELITE BIO, INC. Chief Executive Officer and director Yu-Hsin Lin acquired 5,000 ordinary shares on October 29, 2026, as restricted stock units vested after certain performance criteria were met. The award was granted on September 15, 2025. Lin held 187,949 ordinary shares directly after the transaction. No Rule 10b5-1 plan is reported.
BELITE BIO, INC. (BLTE) director Wan-Shan Chen exercised options to acquire 13,796 ordinary shares on September 24, 2026, at an exercise price of $0.4386 per share. Chen's direct ordinary-share holdings were 37,259 following the exercise; the reported option position following the transaction was 0.
Belite Bio (BLTE) received Nasdaq approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Global Select Market will commence at the open of market on October 19, 2026, under the company’s existing ticker symbol, BLTE. The company describes Global Select as the highest of Nasdaq’s three market tiers.
Belite Bio says the transfer reflects compliance with the market’s more stringent financial and liquidity standards. It expects the move to enhance visibility among institutional investors, improve liquidity and broaden market recognition. Belite Bio is a clinical-stage drug development company focused on degenerative retinal diseases and certain metabolic diseases.
Belite Bio, Inc. Chief Medical Officer Hendrik Peter Scholl reported that Bioptima Ltd. indirectly sold 500 American depositary shares on October 1, 2026. The sales were made under a Rule 10b5-1 trading plan adopted June 25, 2026. Reported per-share prices across the sale tranches ranged from $163.6250 to $170.0200; each American depositary share represents one ordinary share.
Belite Bio, Inc. (BLTE) is the issuer for a proposed sale of 4,000 American Depositary Shares, each representing one ordinary share, with an aggregate market value of $679,280. The remarks name Bioptima AG as the seller and describe Hendrik Peter Scholl as a director; the relationship field identifies Scholl as an officer. The shares are to be sold today or within three months from October 1, 2026, and J.P. Morgan Securities LLC is named as broker.
BELITE BIO, INC (BLTE) disclosed that Chief Executive Officer and director Yu-Hsin Lin sold a total of 100,435 American depositary shares of the company in open‑market transactions on September 4 and September 8, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on December 23, 2025, at weighted average prices within disclosed ranges between $180 and $198.37 per share.
BELITE BIO, INC (BLTE) director and Chief Financial Officer Chuang Hao-Yuan reported open-market sales of 67,395 American depositary shares on September 4 and September 8, 2026. The ADSs were sold at weighted average prices across ranges from $180 to $198.335 per ADS, pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.
BELITE BIO, INC (BLTE) announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour, and Welfare for tinlarebant as a once-daily oral treatment for Stargardt disease type 1 (STGD1), under the Sakigake Designation System, an expedited review pathway for innovative drugs.
STGD1 is a rare inherited retinal disease with no approved treatments, affecting an estimated 9,500 people in Japan. Tinlarebant, Belite Bio’s lead candidate, has received multiple regulatory designations globally and is supported by a Phase 3 STGD1 trial that met its primary endpoint, with additional Phase 2/3 and Phase 3 trials ongoing in STGD1 and geographic atrophy.
BELITE BIO, INC director and Chief Financial Officer Hao-Yuan Chuang reported selling a total of 367 American depositary shares of the company on August 12, 2026, in two open-market transactions. Each sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.